drug
(adapalene + benzoyl peroxide + clindamycin phosphate)
Marketedupdated 5mo agoby Bausch Health US LLC
Approvedcommunity read0 votes
all catalysts(0)
nothing on the calendar yet
Trials studying (adapalene + benzoyl peroxide + clindamycin phosphate)
Patent cliff
source: FDA Orange Bookfirst barrier falls
Oct 20, 2026
18 days
Earliest of all listed patents + FDA exclusivities. Generic / biosimilar entry typically only becomes possible AFTER both patent and exclusivity barriers expire.
patents (8)
- Dec 28, 2040formulationUS 11389467
- Jul 31, 2040formulationUS 12128059
- Jul 31, 2040formulationUS 12133859
- Jul 31, 2040formulationUS 12138278
- Aug 5, 2029formulationUS 82884342.8y
- Jun 3, 2029formulationUS 102200492.7y
- Jun 3, 2029method-of-use (U-3713)US 106249182.7y
- Jun 3, 2029formulationUS 95612082.7y
FDA exclusivities (1)
- Oct 20, 2026NPNP18d
News(0)
no news has mentioned this drug yet
Data sources
last refreshed 1h ago
Found something off?
comments(0)
5-min edit window · permanent after that